Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

Illumina Launches Infinium® HTS-24 Arrays

Published: Thursday, October 10, 2013
Last Updated: Thursday, October 10, 2013
Bookmark and Share
Illumina’s most popular arrays will be deployed on new affordable format.

Illumina, Inc. has launched an advanced high-throughput screening (HTS) array format that significantly increases the number of samples that can be processed on the Infinium® BeadChip family of genotyping arrays.

Illumina’s Infinium assay leverages proven chemistries on a new 24-sample HTS BeadChip that supports up to 750,000 markers per sample and increases scanning capacity by up to three-fold.

“We're excited to introduce this new array format as it enables our customers to perform larger, more powerful studies that enhance discovery,” said Christian Henry, Senior Vice President and General Manager, Genomic Solutions at Illumina.

Henry continued, “The 24-sample HTS BeadChip strengthens Illumina’s leading position in the array market and further demonstrates our ability to continue innovation on our array platform, providing customers with high-quality, high-throughput genotyping solutions. The new format allows us to offer breakthrough pricing per sample which is important to enable direct-to-consumer, biobanking, basic research, and agricultural applications.”

Illumina’s HumanOmniExpress BeadChip will be the first standard array available on the 24-sample HTS BeadChip, part of a portfolio of whole-genome genotyping arrays with new affordable pricing.

This powerful array contains approximately 700,000 markers including the latest updates from the 1,000 Genomes Project strategically selected to capture the greatest amount of common SNP variation and drive the discovery of novel associations with traits and disease.

It can also include up to 50,000 custom markers, making it ideal for those interested in large genotyping studies such as core labs, genome centers, and biobanks.

“We are very happy with the quality of data we obtained using the Illumina Infinium technologies,” said Mark Kelleher, Director of Laboratory Operations at 23andMe. “We are now very excited to deploy the higher-throughput BeadChips to enhance our ability to process larger volumes of samples as we expand our customer base.”

The first consortium-designed array on the 24-sample HTS BeadChip will leverage the new format and affordable pricing to help researchers explore the association between variants to five common cancers - breast, ovarian, colon, lung, and prostate.

The Infinium OncoArray-530K BeadChip (OncoArray), designed in collaboration with leading experts from the OncoArray consortium and enabled by the development of the 24-sample HTS BeadChip, delivers the core content found on Illumina’s Infinium HumanCore array along with approximately 250,000 additional candidate variants identified by OncoArray consortium members and room for 100,000 markers of semi-custom content.

The consortium members are planning a study of unprecedented size which will use the OncoArray to analyze over 425,000 samples and detect subtle associations within and between cancer types.

“The OncoArray is a major new tool for providing future insights into the relationship between genetic variants and cancer predisposition,” said Doug Easton, Professor of Genetic Epidemiology at Strangeways Research Laboratory, University of Cambridge, and a leader of the OncoArray consortium. “It was great working with Illumina to develop the OncoArray. The array contains the custom content we need, in a high-throughput format that will make our large-scale study feasible and should lead to a whole new wave of discoveries.”

The HumanOmniExpress BeadChip is now shipping in the 24-sample HTS format. The OncoArray, iSelect, HumanCoreExome, and HumanCore BeadChips in the 24-sample HTS format are expected to begin shipping in Q1 2014.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Verinata Health's verifi® Prenatal Test Available through the California Prenatal Screening Program
verifi® prenatal test will be available to pregnant women in California.
Tuesday, November 05, 2013
Illumina Acquires Advanced Liquid Logic
Acquisition a key component in the development of complete sample-to-answer solutions for next-generation sequencing.
Wednesday, July 24, 2013
Caris Life Sciences Selects Illumina’s MiSeq® System
Collaboration enhances breadth and depth of therapeutic information to help oncologists better personalize cancer treatment.
Friday, November 09, 2012
BGI Purchases 128 Illumina HiSeq™ 2000 Sequencing Systems
Acquisition puts Beijing Genomics Institute on path to become world's largest sequencing facility.
Thursday, January 14, 2010
Expression Analysis Purchases its First Illumina Genome Analyzer
Illumina's Genome Analyzer sequencing technology will support EA's new plant and animal genomic services.
Friday, January 09, 2009
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
World’s First Therapeutic Venom Database
Open-source library describes nearly 43,000 effects on the human body.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Potential Persistent Tuberculosis Treatment
Researchers have discovered several first-in-class compounds that target hidden TB infections by attacking a critical process the bacteria use to survive in the hostile environment of the lungs.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
The Do’s and Don’ts of SPR Experiments
Surface Plasmon Resonance (SPR) is a technique that is becoming more widely used, particularly by anyone who wants to obtain accurate on (association) and off (dissociation) rates for biomolecular binding.
Long-Sought Protein Sensor for the ‘Sixth Sense’ Discovered
In a study led by scientists from The Scripps Research Institute (TSRI)the sensor protein for propioception has been identified.
New Anti-Malarial Drug Screening Model
University of South Florida researchers demonstrate novel chemogenomic profiling to identify drug targets for the most lethal strain of malaria.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos